JP2015536654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536654A5 JP2015536654A5 JP2015543521A JP2015543521A JP2015536654A5 JP 2015536654 A5 JP2015536654 A5 JP 2015536654A5 JP 2015543521 A JP2015543521 A JP 2015543521A JP 2015543521 A JP2015543521 A JP 2015543521A JP 2015536654 A5 JP2015536654 A5 JP 2015536654A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- dystonia
- bont
- neurotoxin
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims 52
- 108030001720 Bontoxilysin Proteins 0.000 claims 29
- 208000010118 dystonia Diseases 0.000 claims 24
- 208000014094 Dystonic disease Diseases 0.000 claims 23
- 238000000034 method Methods 0.000 claims 17
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 13
- 101710138657 Neurotoxin Proteins 0.000 claims 12
- 239000002581 neurotoxin Substances 0.000 claims 12
- 231100000618 neurotoxin Toxicity 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 208000004350 Strabismus Diseases 0.000 claims 6
- 208000005392 Spasm Diseases 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 208000012661 Dyskinesia Diseases 0.000 claims 3
- 206010020880 Hypertrophy Diseases 0.000 claims 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 3
- 208000002033 Myoclonus Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 230000002920 convulsive effect Effects 0.000 claims 3
- 239000002537 cosmetic Substances 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 229940126601 medicinal product Drugs 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 230000020978 protein processing Effects 0.000 claims 3
- 230000017854 proteolysis Effects 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010013952 Dysphonia Diseases 0.000 claims 2
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 2
- 208000004095 Hemifacial Spasm Diseases 0.000 claims 2
- 208000008454 Hyperhidrosis Diseases 0.000 claims 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 2
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010044074 Torticollis Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 201000003426 X-linked dystonia-parkinsonism Diseases 0.000 claims 2
- 201000000621 achalasia Diseases 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 206010005159 blepharospasm Diseases 0.000 claims 2
- 230000000744 blepharospasm Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013592 cell lysate Substances 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000000744 eyelid Anatomy 0.000 claims 2
- 230000037315 hyperhidrosis Effects 0.000 claims 2
- 208000018197 inherited torticollis Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000003127 knee Anatomy 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 230000003387 muscular Effects 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 210000005070 sphincter Anatomy 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 210000000689 upper leg Anatomy 0.000 claims 2
- 210000001260 vocal cord Anatomy 0.000 claims 2
- 241000567030 Ampulloclitocybe clavipes Species 0.000 claims 1
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 208000016583 Anus disease Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010059237 Auriculotemporal syndrome Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010069632 Bladder dysfunction Diseases 0.000 claims 1
- 208000004130 Blepharoptosis Diseases 0.000 claims 1
- 208000019352 Blepharospasm-oromandibular dystonia syndrome Diseases 0.000 claims 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims 1
- 206010072043 Central nervous system haemorrhage Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 241000193464 Clostridium sp. Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000270722 Crocodylidae Species 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000001692 Esotropia Diseases 0.000 claims 1
- 201000005538 Exotropia Diseases 0.000 claims 1
- 206010015995 Eyelid ptosis Diseases 0.000 claims 1
- 206010068737 Facial asymmetry Diseases 0.000 claims 1
- 206010063006 Facial spasm Diseases 0.000 claims 1
- 208000009531 Fissure in Ano Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010056696 Gaze palsy Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000004041 Gustatory Sweating Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 201000005190 Meige syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims 1
- 208000037158 Partial Epilepsies Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 206010035628 Pleurothotonus Diseases 0.000 claims 1
- 206010036346 Posterior capsule opacification Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 206010041235 Snoring Diseases 0.000 claims 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 1
- 206010058571 Spinal cord infarction Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000003028 Stuttering Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 206010042364 Subdural haemorrhage Diseases 0.000 claims 1
- 206010043101 Talipes Diseases 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 241000469816 Varus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000013142 Writer cramp Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 210000001099 axilla Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 201000007293 brain stem infarction Diseases 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 201000011228 clubfoot Diseases 0.000 claims 1
- 238000012937 correction Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000000959 ear middle Anatomy 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000007186 focal epilepsy Diseases 0.000 claims 1
- 201000002865 focal hand dystonia Diseases 0.000 claims 1
- 210000002683 foot Anatomy 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 238000007373 indentation Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 208000011977 language disease Diseases 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000003784 masticatory muscle Anatomy 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 206010029864 nystagmus Diseases 0.000 claims 1
- 201000002851 oromandibular dystonia Diseases 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 201000003004 ptosis Diseases 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 201000002899 segmental dystonia Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000002849 spasmodic dystonia Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000003813 thumb Anatomy 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 210000001942 upper esophageal sphincter Anatomy 0.000 claims 1
- 206010046947 vaginismus Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000037418 vocal dysfunction Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/073283 WO2014079495A1 (en) | 2012-11-21 | 2012-11-21 | Methods for the manufacture of proteolytically processed polypeptides |
| EPPCT/EP2012/073283 | 2012-11-21 | ||
| PCT/GB2013/053072 WO2014080206A1 (en) | 2012-11-21 | 2013-11-21 | Methods for the manufacture of proteolytically processed polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018208320A Division JP2019030333A (ja) | 2012-11-21 | 2018-11-05 | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015536654A JP2015536654A (ja) | 2015-12-24 |
| JP2015536654A5 true JP2015536654A5 (enExample) | 2016-12-28 |
Family
ID=47216287
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535999A Active JP6156954B2 (ja) | 2012-11-21 | 2012-11-21 | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
| JP2015543521A Pending JP2015536654A (ja) | 2012-11-21 | 2013-11-21 | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
| JP2018208320A Pending JP2019030333A (ja) | 2012-11-21 | 2018-11-05 | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535999A Active JP6156954B2 (ja) | 2012-11-21 | 2012-11-21 | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018208320A Pending JP2019030333A (ja) | 2012-11-21 | 2018-11-05 | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10087432B2 (enExample) |
| JP (3) | JP6156954B2 (enExample) |
| KR (4) | KR102083373B1 (enExample) |
| CN (5) | CN120118892A (enExample) |
| AR (3) | AR093578A1 (enExample) |
| AU (2) | AU2012395188B2 (enExample) |
| BR (2) | BR112015003591B1 (enExample) |
| CA (2) | CA3062150C (enExample) |
| IN (1) | IN2015DN01449A (enExample) |
| MX (3) | MX381995B (enExample) |
| RU (2) | RU2673910C2 (enExample) |
| TW (5) | TW201839134A (enExample) |
| UA (2) | UA111795C2 (enExample) |
| WO (2) | WO2014079495A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| JP6156954B2 (ja) | 2012-11-21 | 2017-07-05 | イプセン バイオイノベーション リミテッド | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
| US10408837B2 (en) * | 2013-12-09 | 2019-09-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Peptide substrates recognizable by type E botulinum neurotoxin |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| BR112016027773B1 (pt) * | 2014-05-29 | 2023-12-26 | Procell Therapeutics Inc. | Proteína recombinante célula-penetrante de toxina botulínica,composição farmacêutica, composição para um agente dérmico externo e composição cosmética |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3263710A1 (en) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| CA3077385A1 (en) * | 2017-10-13 | 2019-04-18 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin a subtype 6 and pharmacological methods of use |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| WO2020222315A1 (ko) * | 2019-04-29 | 2020-11-05 | 주식회사 바이오셀트란 | 피부 또는 세포 투과능이 우수한 피부 주름 개선 또는 치료용 조성물 |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| TW202426039A (zh) | 2020-03-16 | 2024-07-01 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| MA66538B1 (fr) | 2021-09-16 | 2026-03-31 | Ipsen Biopharm Limited | Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale |
| CA3228712A1 (en) | 2021-09-23 | 2023-03-30 | Nicolae GRIGORE | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| AU2022392458A1 (en) | 2021-11-22 | 2024-05-02 | Ipsen Biopharm Limited | Treatment of pain |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202307439D0 (en) | 2023-05-18 | 2023-07-05 | Ipsen Biopharm Ltd | Treatment of a headache disorder with botylinum neurotoxin a |
| US20250101484A1 (en) | 2023-09-27 | 2025-03-27 | Pharmaessentia Corporation | Method to increase drug substance yield |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| AU2023471835A1 (en) | 2023-11-01 | 2026-04-30 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| DE102025101336A1 (de) * | 2024-01-19 | 2025-07-24 | Abbvie Inc. | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
| US7227010B2 (en) * | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US8153397B2 (en) * | 1993-09-21 | 2012-04-10 | The United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| AU2907695A (en) * | 1994-08-08 | 1996-03-07 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US6967088B1 (en) | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| DE19856897A1 (de) | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
| EP2267008B1 (en) * | 1999-08-25 | 2014-07-02 | Allergan, Inc. | Activatable recombinant neurotoxins |
| US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
| US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| WO2002015700A1 (en) | 2000-08-24 | 2002-02-28 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
| TW526437B (en) * | 2001-08-08 | 2003-04-01 | Macronix Int Co Ltd | Photolithography rework analysis method and system |
| US20040013687A1 (en) * | 2002-05-31 | 2004-01-22 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| US20040018589A1 (en) * | 2002-07-25 | 2004-01-29 | Jun Zhong | Method for producing biologically active botulinum neurotoxins through recombinant DNA technique |
| ATE541047T1 (de) | 2002-08-01 | 2012-01-15 | Univ California | Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen |
| AU2003272800A1 (en) * | 2002-10-01 | 2004-04-23 | University Of Maryland | Methods for identifying inhibitors of botulinum neurotoxins |
| US7341843B2 (en) | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| US20080171347A1 (en) | 2003-04-11 | 2008-07-17 | Atassi M Zouhair | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
| US20050169942A1 (en) * | 2003-10-07 | 2005-08-04 | Allergan, Inc. | Novel DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain for production of therapeutics |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| WO2006017749A2 (en) * | 2004-08-04 | 2006-02-16 | Allergan, Inc. | Optimizing expression of active botulinum toxin type a |
| EP1982997B1 (en) * | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| EP1861419B1 (en) * | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| US7465457B2 (en) * | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| DK2154151T3 (da) * | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
| US9072735B2 (en) | 2005-10-03 | 2015-07-07 | Yong Qian | Proteinases destroy cancer tumor's solid structure and kill cancer cells locally |
| US7464917B2 (en) * | 2005-10-07 | 2008-12-16 | Appiled Materials, Inc. | Ampoule splash guard apparatus |
| DE102005051789B4 (de) * | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| AU2007272515B2 (en) * | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| KR100677871B1 (ko) * | 2006-09-11 | 2007-02-02 | 주식회사 메가젠 | 골충진재 성형 장치 및 골충진재 성형 방법 |
| EP2167119B1 (en) * | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemically modified peptides with improved immunogenicity |
| US8486422B2 (en) * | 2007-07-26 | 2013-07-16 | Allergan, Inc. | Methods of activating clostridial toxins |
| EP2023327A1 (en) * | 2007-07-27 | 2009-02-11 | Foxboro Eckardt Gmbh | Operation voltage controller and method for controlling an operation voltage controller |
| CA2703370A1 (en) * | 2007-10-23 | 2009-04-30 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
| BRPI0819212A2 (pt) * | 2007-10-23 | 2015-06-16 | Allergan Inc | Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio |
| MY155049A (en) * | 2008-03-14 | 2015-08-28 | Allergan Inc | Immuno-based botolinum toxin serotype a activity assay |
| US9000131B2 (en) | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| WO2010085473A1 (en) * | 2009-01-20 | 2010-07-29 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
| BRPI1008885B1 (pt) * | 2009-02-19 | 2021-09-28 | Merz Pharma Gmbh & Co. Kgaa | Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição |
| KR102017327B1 (ko) * | 2009-03-13 | 2019-09-03 | 알러간, 인코포레이티드 | 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포 |
| WO2010124998A1 (en) * | 2009-04-27 | 2010-11-04 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities |
| US20100303783A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases |
| US20100303757A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
| AU2010267963B2 (en) * | 2009-07-02 | 2015-09-24 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
| US10246492B2 (en) * | 2009-10-16 | 2019-04-02 | Biomadison, Inc. | Botulinum assay with synaptobrevin substrate moiety |
| WO2011047265A1 (en) * | 2009-10-16 | 2011-04-21 | Biosentinel, Inc. | Resonance energy transfer assay with synaptobrevin substrate moiety |
| JP2013514091A (ja) | 2009-12-16 | 2013-04-25 | アラーガン、インコーポレイテッド | 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素 |
| US20130245227A1 (en) * | 2010-01-15 | 2013-09-19 | Allergan, Inc. | Methods of activating clostridial toxins |
| SI2528940T1 (sl) * | 2010-01-25 | 2014-07-31 | Allergan, Inc. | Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko |
| AT511002A1 (de) * | 2011-02-08 | 2012-08-15 | Univ Innsbruck | Verfahren zur verformung von cellulosecarbamat und produkte, die nach diesem verfahren hergestellt werden |
| US20120207734A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases |
| WO2012112432A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| EP2524963B1 (en) * | 2011-05-19 | 2018-10-31 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| JP6162135B2 (ja) * | 2011-11-09 | 2017-07-12 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 短縮された生物活性を示す神経毒 |
| CA2866595A1 (en) * | 2012-03-07 | 2013-09-12 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determining neurotoxin activity based on a modified luciferase |
| KR101729710B1 (ko) * | 2012-04-09 | 2017-04-24 | 서울대학교산학협력단 | 물에 안정하게 분산되는 멜라닌 나노입자를 포함하는 핵자기 공명 영상 조영제 |
| MX359480B (es) * | 2012-05-30 | 2018-09-28 | President And Fellows Of Harvard College Star | Neurotoxina botulínica diseñada. |
| WO2014029497A1 (en) * | 2012-08-20 | 2014-02-27 | Merz Pharma Gmbh & Co. Kgaa | Novel method for the manufacturing of recombinant proteins harbouring an n-terminal lysine |
| JP6156954B2 (ja) * | 2012-11-21 | 2017-07-05 | イプセン バイオイノベーション リミテッド | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
| WO2014079497A1 (en) * | 2012-11-22 | 2014-05-30 | Drugs For Neglected Diseases Initiative (Dndi) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of same |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| US11897921B2 (en) * | 2014-12-09 | 2024-02-13 | New York University | Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain |
| US9913875B2 (en) * | 2015-03-16 | 2018-03-13 | California Institute Of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
| GB201505306D0 (en) * | 2015-03-27 | 2015-05-13 | Ipsen Biopharm Ltd | Chimeric polypeptides |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| UA127310C2 (uk) * | 2016-05-16 | 2023-07-19 | Презідент Енд Феллоуз Оф Гарвард Колледж | Спосіб очищення і активації ботулінічного нейротоксину |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
-
2012
- 2012-11-21 JP JP2015535999A patent/JP6156954B2/ja active Active
- 2012-11-21 KR KR1020177012803A patent/KR102083373B1/ko active Active
- 2012-11-21 AU AU2012395188A patent/AU2012395188B2/en active Active
- 2012-11-21 CA CA3062150A patent/CA3062150C/en active Active
- 2012-11-21 MX MX2019000098A patent/MX381995B/es unknown
- 2012-11-21 WO PCT/EP2012/073283 patent/WO2014079495A1/en not_active Ceased
- 2012-11-21 RU RU2015107240A patent/RU2673910C2/ru active
- 2012-11-21 BR BR112015003591-4A patent/BR112015003591B1/pt active IP Right Grant
- 2012-11-21 MX MX2015002390A patent/MX363788B/es active IP Right Grant
- 2012-11-21 US US14/423,222 patent/US10087432B2/en active Active
- 2012-11-21 CN CN202510029795.7A patent/CN120118892A/zh active Pending
- 2012-11-21 KR KR1020187018705A patent/KR20180077343A/ko not_active Ceased
- 2012-11-21 KR KR1020157004071A patent/KR102083371B1/ko active Active
- 2012-11-21 CN CN201280075874.2A patent/CN104870468B/zh active Active
- 2012-11-21 CA CA2880897A patent/CA2880897C/en active Active
- 2012-11-21 UA UAA201502409A patent/UA111795C2/uk unknown
- 2012-11-21 CN CN202010161444.9A patent/CN111454931A/zh active Pending
-
2013
- 2013-11-21 CN CN201380060742.7A patent/CN104797595B/zh active Active
- 2013-11-21 TW TW107123545A patent/TW201839134A/zh unknown
- 2013-11-21 MX MX2015006324A patent/MX2015006324A/es unknown
- 2013-11-21 RU RU2015124069A patent/RU2015124069A/ru not_active Application Discontinuation
- 2013-11-21 CN CN202010771933.6A patent/CN112048009A/zh active Pending
- 2013-11-21 TW TW102142485A patent/TW201439322A/zh unknown
- 2013-11-21 WO PCT/GB2013/053072 patent/WO2014080206A1/en not_active Ceased
- 2013-11-21 KR KR1020157016356A patent/KR20150085844A/ko not_active Ceased
- 2013-11-21 UA UAA201506009A patent/UA117231C2/uk unknown
- 2013-11-21 TW TW107123543A patent/TW201839133A/zh unknown
- 2013-11-21 TW TW107123546A patent/TWI713862B/zh active
- 2013-11-21 BR BR112015010550A patent/BR112015010550A8/pt not_active Application Discontinuation
- 2013-11-21 AR ARP130104298A patent/AR093578A1/es active IP Right Grant
- 2013-11-21 JP JP2015543521A patent/JP2015536654A/ja active Pending
- 2013-11-21 TW TW107123542A patent/TWI709649B/zh active
-
2015
- 2015-02-20 IN IN1449DEN2015 patent/IN2015DN01449A/en unknown
-
2017
- 2017-08-30 AU AU2017221793A patent/AU2017221793B2/en active Active
-
2018
- 2018-08-20 US US16/105,120 patent/US10808236B2/en active Active
- 2018-11-05 JP JP2018208320A patent/JP2019030333A/ja active Pending
-
2020
- 2020-02-06 AR ARP200100322A patent/AR118019A2/es unknown
- 2020-07-14 US US16/928,107 patent/US11441141B2/en active Active
-
2022
- 2022-07-15 US US17/812,800 patent/US20230015772A1/en not_active Abandoned
- 2022-11-09 AR ARP220103075A patent/AR127620A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536644A5 (enExample) | ||
| RU2015107240A (ru) | Способ производства протеолитически процессированных полипептидов | |
| JP6994523B2 (ja) | 組換えボツリヌス菌神経毒の生産 | |
| JP5897784B2 (ja) | ボツリヌス毒素の神経毒成分の高頻度適用 | |
| JP7007392B2 (ja) | 唾液腺炎の治療におけるボツリヌス神経毒素の改善された使用 | |
| EA039105B1 (ru) | Катионные нейротоксины | |
| JP2015519362A5 (enExample) | ||
| RU2017134357A (ru) | Сконструированный ботулинический нейротоксин | |
| JP2009541396A5 (enExample) | ||
| WO2009015840A2 (en) | Polypeptide for targeting of neural cells | |
| KR20220154738A (ko) | 사지 경직을 치료하기 위한 변형된 보툴리눔 신경독소 | |
| KR20230144618A (ko) | 변형된 신경독소의 단일 사슬 폴리펩티드 및 이의 용도 | |
| JP2021514674A5 (enExample) | ||
| CA3228712A1 (en) | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject | |
| JP2015504304A (ja) | ポリ−グリシンを伴う修飾神経毒及びその使用 | |
| CN121534167A (zh) | 修饰的BoNT/A用于颈肌张力障碍的治疗 | |
| CA3153670A1 (en) | Use of chlostridial neurotoxin variant for the treatment of neurological disorders | |
| CN112739320A (zh) | 肉毒杆菌神经毒素血清型e的治疗和美容用途 | |
| JP2014529395A5 (enExample) | ||
| JP2019531698A (ja) | 活性化クロストリジウム神経毒の製造 | |
| JP5889305B2 (ja) | 組換え神経毒ポリペプチドの選択的製造 | |
| JP2014529395A (ja) | ボツリヌス神経毒のタンパク質分解的切断の改変 | |
| CN119110728A (zh) | 颈肌张力障碍的治疗 | |
| CN119095579A (zh) | 上面部纹的治疗 | |
| EP2218783A1 (en) | Novel method for the manufacturing of neurotoxins |